Intravitreal fluocinolone acetonide implant for chronic postoperative cystoid macular edema - two years results.
Abstract
Purpose: We report visual and anatomical outcomes of chronic postoperative macular edema treated with a fluocinolone acetonide intravitreal implant.
Method: Retrospective study of chronic, post-surgical CME treated with a fluocinolone acetonide intravitreal implant. Best registered visual acuity (BRVA), central retinal thickness (CRT), and Goldmann tonometry intraocular pressure (IOP) were assessed over 24 months. The need for IOP lowering treatment, top-up therapy during follow-up, and complications were also assessed.
Results: We analyzed 16 consecutive eyes of 16 patients with chronic, post-surgical CME treated with fluocinolone acetonide intravitreal implant. Surgical indications included cataract surgery, vitrectomy plus membrane peeling and combined phaco-vitrectomy. Baseline mean BRVA of 0.8?±?0.65 logMAR improved to 0.60?±?0.4 logMAR (p?=?0.02) at 12 months and to 0.7?±?0.5 logMAR (p?=?0.32) at 24 months. At month 12, BRVA improved in 11 eyes, stabilized in 4 eyes, and decreased in 1 eye. At month 24, VA remained improved in 5 eyes, remained stabilized in 5 eyes, and decreased in 1 eye. Mean CRT decreased from 524?±?132?μm at baseline to 389?μm at month 3, 347?μm at month 6, 355?±?106?μm (p?=?0.0003) at month 12, and 313?±?83?μm (p?=?0.0001) at month 24. At 12 months, CRT improved in 13 eyes and remained unchanged in 2 eyes. At 24 months, CRT improved further in 8 eyes, and stabilized in 3 eyes. Increased IOP (≥21?mmHg) was observed only in 4 eyes, all successfully managed with topical medication. No further side effects were observed in any patient.
Conclusion: Visual and anatomic improvements were achieved by a single fluocinolone acetonide implant with few side effects up to 24 months in CME eyes with a long and heavy prior treatment history.